I very much appreciate the data presented by Szarfman and colleagues, which were prepared using the Food and Drug Administration AERS database and the MGPS statistical algorithm. These new data provide further support to the conclusions presented in our article,1 and I thank them for presenting their findings. The prominent occurrence of pramipexole seen in their data adds support to the position that a relationship between that particular dopamine agonist and impulsive behaviors is strong. I further contend that disproportionate dopamine D3 agonism (especially seen with pramipexole) as a substrate for pathologic gambling seems too obvious to ignore.
Dodd ML. Association Between Pathologic Gambling and Parkinsonian Therapy as Detected in the Food and Drug Administration Adverse Event Database—Reply. Arch Neurol. 2006;63(2):300. doi:10.1001/archneur.63.2.300-a